These higher-dose formulations remain under investigation
JPMorgan estimates the overall sector decline to be between $30-55 billion in annual revenue by 2030 for the food and beverage sector as a whole
3 Works cited FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, accessed February 2, 2026, Semaglutide Shortage Resolved McDermott Will & Schulte, accessed February 2, 2026, GLP-1 Update: Court Backs FDA in Tirzepatide Compounding Case, accessed February 2, 2026, The Return of 503B Compounding of GLP-1 Medications Frier Levitt, accessed February 2, 2026, The Strategic Imperative of Pharmaceutical Competitor Analysis: A Comprehensive Guide for 2026 and Beyond DrugPatentWatch, accessed February 2, 2026, Maximizing ROI on Drug Development by Monitoring Competitive Patent Portfolios, accessed February 2, 2026, Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act FDA, accessed February 2, 2026, GLP-1 Weight-Loss Drugs Off Shortage List
Profile 7: Patients Requiring In-Person Medication Management for Comorbidities Patients on warfarin, narrow therapeutic index drugs, or insulin regimens that will require dose titration as weight changes should be managed by an in-person prescriber who can order labs, adjust doses, and monitor for interactions in real time
Surrogate endpoints are measurable markers like blood pressure and cholesterol that correlate with disease outcomes but dont directly measure events
What causes it and how to help quiet it, according to experts - CBS News, accessed April 22, 2025, Understanding Food Noise and How GLP-1 Medications Help Silence It - Flow Wellness, accessed April 22, 2025, GLP-1 Receptor Agonists and Related Mental Health Issues
